You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Anti-HBs immune response in subjects according to their pre-challenge dose serostatus (ATP cohort for immunogenicity)

From: Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

Group Pre-challenge status (mIU/mL) N ≥10 mIU/mL ≥100 mIU/mL GMC
% or Value (95% CI)
HBV_2D <3.3 6 100 (54.1 - 100) 66.7 (22.3 - 95.7) 277.5 (24.7 - 3117.3)
  3.3 to <10 6 100 (54.1 - 100) 83.3 (35.9 - 99.6) 821.7 (142.8 - 4729.5)
  10 to 100 26 100 (86.8 - 100) 100 (86.8 - 100) 6117.3 (2875.1 - 13015.7)
  ≥100 15 100 (78.2 - 100) 100 (78.2 - 100) 49745.4 (24663.9 - 100332.9)
HBV_3D <3.3 1 100 (2.5 - 100) 0.0 (0.0 - 97.5) 37.4 (-)
  3.3 to <10 0 - - -
  10 to 100 9 100 (66.4 - 100) 100 (66.4 - 100) 6048.5 (2414.6 - 15150.9)
  ≥100 11 100 (71.5 - 100) 100 (71.5 - 100) 65723.7 (34920.1 - 123699.6)
Pooled <3.3 7 100 (59.0 - 100) 57.1 (18.4 - 90.1) 208.4 (26.3 - 1648.7)
  3.3 to <10 6 100 (54.1 - 100) 83.3 (35.9 - 99.6) 821.7 (142.8 - 4729.5)
  10 to 100 35 100 (90.0 - 100) 100 (90.0 - 100) 6099.5 (3396.3 - 10954.1)
  ≥100 26 100 (86.8 - 100) 100 (86.8 - 100) 55967.0 (35483.1 - 88276.2)
  1. N = number of subjects with available results; 95% CI = exact 95% confidence interval
  2. GMC = geometric mean concentrations